Pay in 4 interest-free payments of $6.03 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
Moving forward, high-quality multicenter clinical trials with larger sample sizes, longer follow-up, and standardized endpoints are essential to validate efficacy
Krolewski Research Division, Joslin Diabetes Center and Harvard Medical School Kevin Duffin Vice President, Aging Research, Eli Lilly Jonathan Wilson Senior Director, Eli Lilly and Company Pavo Imre Senior Medical Director, Eli Lilly & Co, Vienna Fergus Fleming Co-founder, Executive Director and CTO, RenalytixAI Anna Nowak-Szwed, Eiichiro Satake, and Sok Cin Tye Joslin Diabetes Center / Harvard Medical School researchers advancing translational proteomics and kidney disease biomarker research #cardiometabolic #immunology #pathology #Proteomics #KidneyDisease #Nephrology #Diabetes #Biomarkers #GLP1 #Tirzepatide #Olink #PrecisionMedicine #TranslationalResearch #EliLilly To view or add a comment, sign in 88% of patients held steady or improved in Phase 2
It is legally compoundable now with no regulatory uncertainty
02 Multi-Use Option Allows multiple uses from a single vial over time
Lamothe J, Khurana S, Tharmalingam S, Williamson C, Byrne CJ, Lees SJ, Khaper N, Kumar A, Tai TC
6, A C and Fig
US$ 26.17
US$ 25.56
US$ 25.82
US$ 20.03
US$ 24.65
